Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Inflammopharmacology ; 26(4): 963-972, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29470694

ABSTRACT

Temporal lobe epilepsy (TLE) is present in 30% of epileptic patients and does not respond to conventional treatments. Bone marrow derived mesenchymal stem cells (BMSCs) induce endogenous neural stem cells, inhibit neurodegeneration, and promote brain self-repair mechanisms. The present study addresses the feasibility of BMSCs transplantation against pilocarpine-induced TLE experimentally. BMSCs were injected either intravenously (IV) or in hippocampus bilaterally (IC). Increased cell count of BMSCs was achieved via IC route. BMSCs treatment ameliorated the pilocarpine-induced neurochemical and histological changes, retained amino acid neurotransmitters to the normal level, downregulated the immunoreactivity to insulin growth factor-1 receptor, synaptophysin, and caspase-3 and reduced oxidative insult and inflammatory markers detected in epileptic model. It is worth noting that BMSCs IC-administered showed more pronounced effects than those administered via IV route. BMSCs transplantation presents a promise for TLE treatment that has to be elucidated clinically.


Subject(s)
Epilepsy, Temporal Lobe/therapy , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/cytology , Animals , Caspase 3/metabolism , Disease Models, Animal , Epilepsy, Temporal Lobe/physiopathology , Hippocampus , Injections, Intravenous , Male , Pilocarpine/toxicity , Rats , Rats, Sprague-Dawley , Receptor, IGF Type 1/metabolism , Synaptophysin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...